Daily Ards Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
Analyzed 8 papers and selected 3 impactful articles.
Selected Articles
1. Inhaled nitric oxide for acute respiratory distress syndrome in adults: a systematic review and meta-analysis.
Across 11 RCTs (n=1302), iNO modestly improved oxygenation but did not reduce mortality (RR 1.07, 95% CI 0.93–1.23). Signals of increased renal replacement therapy raise safety concerns, underscoring selective use and the need for high-quality trials.
Impact: Provides up-to-date, registered evidence synthesis of RCTs clarifying that iNO does not improve survival and may increase renal support needs in adult ARDS.
Clinical Implications: Avoid routine iNO use for adult ARDS; consider iNO only as short-term rescue to transiently improve oxygenation while recognizing potential increase in RRT. Prioritize strategies with proven outcome benefit.
Key Findings
- Across 11 RCTs (n=1302), iNO did not reduce mortality at longest follow-up (RR 1.07; 95% CI 0.93–1.23).
- iNO may slightly improve oxygenation but without patient-centered benefits.
- iNO use may increase the need for renal replacement therapy.
- Only one included trial was at low risk of bias; higher-quality RCTs are needed.
Methodological Strengths
- Prospective registration (PROSPERO CRD42024573383) with comprehensive multi-database search.
- Focus on RCTs with clearly defined primary and secondary outcomes.
Limitations
- Only one trial at low risk of bias; overall evidence quality limited by included studies.
- Potential heterogeneity in iNO dosing, timing, and co-interventions not fully resolved.
Future Directions: Identify phenotypes that may transiently benefit from iNO without renal harm; design adequately powered, low-bias RCTs with standardized dosing and renal safety endpoints.
BACKGROUND: Although inhaled nitric oxide (iNO) is used as a rescue therapy in patients with acute respiratory distress syndrome (ARDS), its impact on patient-centered outcomes remains uncertain. To address this gap, we conducted a systematic review of randomized controlled trials (RCTs) to test the hypothesis that the addition of iNO to standard care improves survival in adult patients with ARDS. METHODS: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and WHO ICTRP for RCTs evaluating iNO in adult patients with ARDS through October 28, 2025. The primary outcome was mortality at the longest follow-up. Secondary outcomes included acute kidney injury (AKI), receipt of renal replacement therapy (RRT), duration of mechanical ventilation, length of intensive care unit stay, length of hospital stay, receipt of extracorporeal membrane oxygenation (ECMO), mean pulmonary artery pressure, partial pressure of arterial oxygen/fraction of inspiratory oxygen (PaO RESULTS: We included 11 RCTs comprising 1302 patients. Only one study was of low risk of bias. iNO therapy may result in no difference in mortality at the longest follow-up (relative risk [RR], 1.07; 95% confidence interval [CI], 0.93-1.23; I CONCLUSIONS: Although iNO may improve oxygenation slightly, it may not confer survival or other patient-centered benefits and may increase the need for RRT. High-quality randomized evidence is needed to guide the optimal patient selection for this therapeutic option. TRIAL REGISTRATION: PROSPERO (registration number: CRD42024573383).
2. Time-dependent effects in consecutive cycles of prone positioning for acute respiratory failure: insights from the PROVENT-C19 Registry.
In 1523 COVID-19 AHRF patients from 53 centers, survivors exhibited greater PaO2/FiO2 improvements and smaller ventilatory ratio increases across prone cycles versus non-survivors. Total prone time did not differ by survival, and longer duration associated with mortality reduction only in the second cycle.
Impact: Links physiologic responses across repeated prone cycles to ICU survival and challenges the assumption that simply extending prone duration beyond early cycles yields mortality benefit.
Clinical Implications: Use oxygenation and ventilatory ratio responses across cycles as dynamic prognostic markers. Consider prioritizing quality of response (e.g., sustained PaO2/FiO2 gains and stable ventilatory ratio) over indiscriminate prolongation beyond the second cycle.
Key Findings
- In all analyzed prone cycles, ICU survivors had higher Δ-PP and Δ-PostPP in PaO2/FiO2 than non-survivors (p ≤ 0.001).
- Ventilatory ratio changes (Δ-PP and Δ-PostPP) were significantly lower in survivors across cycles (p < 0.05).
- Total time spent prone did not differ between survivors and non-survivors [61 (38,84) h vs 58 (32,85) h; p = 0.175].
- Longer prone duration correlated with lower ICU mortality only in the second cycle (OR 0.986; 95% CI 0.978–0.994).
Methodological Strengths
- Large international, multicenter registry (n=1523, 53 centers).
- Serial physiologic measurements beyond the first prone cycle, including PaO2/FiO2 and ventilatory ratio.
Limitations
- Observational design with potential residual confounding.
- Population limited to COVID-19 AHRF; generalizability to non-COVID ARDS is uncertain.
Future Directions: Prospective studies to validate response-based stopping/continuation criteria for subsequent prone cycles and to test tailored duration strategies.
BACKGROUND: Prone positioning is recommended for patients with acute respiratory distress syndrome not only to improve oxygenation, but also to reduce lung stress, and lower mortality. The association between improved oxygenation during prone position and reduced mortality is still controversial. In previous studies, oxygenation improvement during the first prone positioning cycle was linked to lower intensive care unit (ICU) mortality, especially with prolonged duration. However, physiological data during subsequent cycles were lacking. This study aims to explore the association between ICU mortality and physiological responses to prone positioning-such as arterial oxygenation, dead space, and respiratory mechanics-and to assess how the cumulative time spent in prone or supine positions across all studied cycles influences outcomes. METHODS: International registry including adult patients who underwent prone positioning for acute hypoxemic respiratory failure due to COVID-19. We measured the difference for arterial partial pressure of oxygen to inspired fraction of oxygen ratio (PaO2/FiO2) and ventilatory ratio between baseline supine position and at either the end of cycle of prone position (Delta-PP) or re-supination (Delta-PostPP), focusing on the cycles following the first one. RESULTS: We included 1523 patients from 53 centers. Both Delta-PP and Delta-PostPP for PaO2/FiO2 were significantly higher in ICU survivors than in ICU non-survivors for all the analyzed prone positioning cycles (p ≤ 0.001 for all comparisons). Delta-PP and Delta-PostPP for ventilatory ratio were significantly lower in ICU survivors than in ICU non-survivors for all the analyzed prone positioning cycles (p < 0.05 for all comparisons). No difference in the overall time spent in prone position was found between ICU survivors and non-survivors [61 (38, 84) h vs 58 (32, 85) h, respectively, p = 0.175]. The cumulative length of prone position was associated with ICU mortality only for the second prone positioning cycle [OR (95% CI) 0.986 (0.978, 0.994)]. No significant association was observed between the time spent in supine position and ICU mortality for all the analyzed prone positioning cycles. CONCLUSIONS: ICU survivors consistently demonstrated better oxygenation and more stable ventilatory ratio across studied prone positioning cycles, whereas non-survivors showed worsening oxygenation when returning supine and increased ventilatory ratio. Additionally, extending the duration of prone position beyond the second cycle may not significantly impact mortality.
3. Hesperetin alleviates sepsis-associated acute respiratory distress syndrome via the PI3K/Akt/PTEN axis.
Integrating network pharmacology and in vitro assays, hesperetin targeted PI3K-Akt signaling via PTEN upregulation. It reduced pro-inflammatory cytokines, ROS, and apoptosis while increasing IL-10 and PTEN in LPS-stimulated alveolar macrophages.
Impact: Provides mechanistic evidence linking a widely available flavonoid to key ARDS inflammatory pathways, nominating PTEN/PI3K-Akt as a target for sepsis-associated ARDS.
Clinical Implications: Translational potential exists but requires in vivo validation and pharmacokinetic/delivery optimization before any clinical application.
Key Findings
- Network pharmacology identified 87 shared targets (e.g., TNF, IL6, AKT1, STAT3) enriched in the PI3K-Akt pathway.
- Molecular docking showed strong binding affinities to AKT (-7.943 kcal/mol) and PI3K (-7.619 kcal/mol).
- In LPS-induced MH-S alveolar macrophages, hesperetin reduced IL-1β, IL-6, TNF-α, ROS, and apoptosis, and increased IL-10 and PTEN dose-dependently.
- Western blot confirmed inhibition of PI3K-Akt activation via PTEN upregulation.
Methodological Strengths
- Combined in silico network pharmacology with experimental validation.
- Demonstrated dose-dependent effects across multiple readouts (cytokines, ROS, apoptosis, signaling).
Limitations
- In vitro model without in vivo or clinical validation.
- Translational aspects (delivery, pharmacokinetics, toxicity) not addressed.
Future Directions: Validate efficacy in relevant in vivo sepsis-ARDS models; assess dosing, PK/PD, and safety; explore combination strategies targeting PTEN/PI3K-Akt.
Sepsis-associated acute respiratory distress syndrome (ARDS) is a life-threatening condition marked by severe inflammation and oxidative stress, with limited therapeutic options. Hesperetin, a natural citrus flavonoid, has antioxidant and anti-inflammatory properties, but its molecular mechanisms in ARDS remain unclear. To explore the therapeutic potential and mechanisms of hesperetin in sepsis-associated ARDS using network pharmacology and in vitro experiments. Network pharmacology identified common targets of hesperetin and ARDS, followed by protein-protein interaction, Gene Ontology, and KEGG analyses to reveal hub targets and pathways. Molecular docking assessed binding affinities. In vitro, an LPS-induced MH-S alveolar macrophage model was used to evaluate hesperetin's effects on cytokines, reactive oxygen species (ROS), apoptosis, and signaling, with Western blot analysis of PI3K-Akt modulation. Eighty-seven common targets were identified, including TNF, IL6, AKT1, and STAT3, enriched in the PI3K-Akt pathway. Docking confirmed strong affinities for AKT (-7.943 kcal/mol) and PI3K (-7.619 kcal/mol). Hesperetin reduced IL-1β, IL-6, TNF-α, ROS, and apoptosis, while increasing IL-10 and PTEN in a dose-dependent manner. Western blot showed inhibition of PI3K-Akt activation via PTEN upregulation. Hesperetin alleviates sepsis-associated ARDS through multi-target mechanisms, particularly the PTEN/PI3K-Akt axis, supporting its potential as a therapeutic agent.